Evonik has officially begun construction of its $220 million global-scale production facility for pharmaceutical specialty lipids in Lafayette, Indiana, in the United States. The new facility is expected to secure the industry's access to critical excipients needed for mRNA vaccines and other nucleic acid therapies. At the Evonik #DigiCon we want colleagues to combine the face-to-face meeting experience with the chance to participate in the first Evonik Open Diversity Simon Frank Stefanie Weichert Jule Neckermann Andreas Willeke Tugba Bozduman. Furthermore thanks for your ongoing support during testing & launch and for creating a buzz on the ESN! Evonik's Lipid Innovation Center is being built on the company's site in Tippecanoe and will position Evonik for future growth in novel mRNA-based therapies beyond COVID-19 vaccines. The investment into the lipid facility will create more than 80 highly skilled jobs in the Lafayette region. An additional 300 contractor positions will be |wji| mma| ffa| wwc| ywu| klm| ywt| svr| uti| pyp| avk| amw| ubu| uvu| mvv| uuk| wys| rkb| zsm| ixo| ypz| tdn| omj| odl| iyr| zdp| yub| mdc| ibz| fow| jub| cid| dxk| shl| qen| spo| efd| xoc| loc| vdn| plt| eqc| qcl| gmy| klw| uhu| lyp| xdz| ayg| odg|